Prostate Cancer

As part of its Speaking Out video series, CURE talked to Dr. Brian Keith McNeil, on behalf of ZERO Prostate Cancer, about the role of PSMA-PET Imaging versus PSA.

As part of its Speaking Out video series, CURE talked to Dr. Brian Keith McNeil, on behalf of ZERO Prostate Cancer, about understanding Gleason Score and prostate cancer risk.

FDA-authorized AI tools have the potential to help patients with prostate cancer get clearer answers instead of waiting weeks for genomic test results.

Dr. Neal Patel says biopsy results may not fully capture prostate cancer risk, stressing that PSA, stage and disease volume should also guide treatment.

Being diagnosed with a disease like prostate cancer is a very impactful life event, making it vital to have people you love by your side.

A new AI precision medicine test is being used to help clinicians better identify a personalized treatment plan to treat patients with prostate cancer.

The FDA has granted fast track designation to HLD-0915 for metastatic castration-resistant prostate cancer.

About one in six men with grade group 1 prostate cancer have higher-risk disease, showing outcomes vary and biopsy grade may underestimate risk.

A diverticulitis concern led to a prostate cancer diagnosis that shifted a patient's mindset and highlighted the importance of hisloved ones.

After my cancer diagnosis, I planned to go it alone but found unconditional acceptance from the cancer community once I took the first step.

New insights highlight how prostate cancer is now managed as a chronic disease, with emerging treatments and real-world data offering renewed hope for patients.

Carotuximab plus Erleada proved safe in the first 10 patients with metastatic castration-resistant prostate cancer dosed on the phase 2 trial.

Dr. Nicholas James shares why it’s important to identify which patients with high-risk, non-metastatic prostate cancer will benefit from intensified treatment.

The FDA granted fast track designation to TRE-515 plus radioligand therapy for treating PSMA-positive metastatic castration-resistant prostate cancer.

Bob Lane discusses his experience with prostate cancer, and describes what survivorship and cure means to him as someone living with metastatic disease.

Patients with nonmetastatic prostate cancer treated according to NCCN Guidelines are more likely to die of other natural causes than from their cancer.

Real-world data suggest that Erleada may offer an advantage over other treatment options for patients with metastatic castration-sensitive prostate cancer.

Stoboclo and Osenvelt, FDA-approved biosimilars of Prolia and Xgeva, are now available in the U.S. for variois cancers and cancer-related bone conditions.

Dr. Nicholas James discusses why it is important to identify which patients with high-risk prostate cancer will truly benefit from intensified treatment.

June brought major prostate cancer updates, and CURE is sharing the latest FDA approvals, label expansions, and emerging data on the role of AI in care.

I was diagnosed with testicular cancer at 20. I’ve learned to embrace the pauses in life and stand proud as a survivor who won’t be ignored.

Dr. Ravi Munver explained that, for patients who are recently diagnosed with prostate cancer, it is important to explore treatment option with their care.

Illuccix is now FDA approved to help select patients with metastatic prostate cancer for radioligand therapy before chemotherapy.

It’s a bad day when a doctor says you have cancer. It’s a worse day when he says it’s stage prostate cancer with a metastatic lesion.

FDA approves updated labeling for Talzenna plus Xtandi in men with HRR gene-mutated metastatic prostate cancer, showing a 14-month survival benefit.